WO2013038981A1 - 膵疾患マーカーの検出方法 - Google Patents

膵疾患マーカーの検出方法 Download PDF

Info

Publication number
WO2013038981A1
WO2013038981A1 PCT/JP2012/072712 JP2012072712W WO2013038981A1 WO 2013038981 A1 WO2013038981 A1 WO 2013038981A1 JP 2012072712 W JP2012072712 W JP 2012072712W WO 2013038981 A1 WO2013038981 A1 WO 2013038981A1
Authority
WO
WIPO (PCT)
Prior art keywords
pancreatic
pancreatic disease
marker
juice
concentration
Prior art date
Application number
PCT/JP2012/072712
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
博美 佐貫
奈緒 守屋
理惠 片岡
Original Assignee
オリンパス株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オリンパス株式会社 filed Critical オリンパス株式会社
Priority to CN201280043445.7A priority Critical patent/CN103782175A/zh
Priority to EP12832566.9A priority patent/EP2757377A4/en
Publication of WO2013038981A1 publication Critical patent/WO2013038981A1/ja
Priority to US14/199,136 priority patent/US20140186863A1/en

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney

Definitions

  • the present invention relates to a method for detecting a pancreatic disease marker excreted from the pancreas safely and with high performance.
  • Pancreatic cancer has a 5-year survival rate of 5% or less, and is the worst prognosis cancer. The first reason is that there is no effective test method for screening for pancreatic cancer. Secondly, it is difficult to cause symptoms early in pancreatic cancer, and in many cases, it is discovered after pancreatic cancer has progressed. Therefore, it is expected that the prognosis of pancreatic cancer will be greatly improved if a treatable early pancreatic cancer can be detected by a minimally invasive and simple method that can be carried out even by normal screening.
  • Body fluid is an important biological sample for knowing the state of an organ.
  • Pancreatic juice is also an important biological sample for knowing the state of the pancreas, and is used for cytodiagnosis, bicarbonate measurement, bacterial testing, and the like.
  • the search for new markers for pancreatic-related diseases such as pancreatic cancer has been widely conducted.
  • CEA cancerembryonic antigen
  • serum tumor marker is a glycoprotein present on the surface of cancer cells and is known to be highly expressed in pancreatic cancer cells.
  • the concentration of the tumor marker molecule may be diluted with systemic blood, the detection sensitivity in pancreatic cancer was as low as about 50%.
  • pancreatic juice and bile secretion stimulants secretin and CCK
  • pancreatic juice discharged after 30 minutes and 45 minutes is collected from a sonde inserted into the duodenum under fluoroscopy (secretin test).
  • CEA in the pancreatic juice thus obtained is measured.
  • the CEA concentration is reported to be 2.3 to 25 ng / mL in healthy subjects and around 50 ng / mL in patients with pancreatic cancer.
  • the CEA concentrations may be high even in patients suffering from other than pancreatic diseases, and a high CEA concentration in duodenal juice collected after administration of a secretory stimulant did not necessarily indicate the presence of pancreatic cancer.
  • Non-Patent Documents 3 and 4 in endoscopic pancreatography (ERCP), after inserting a catheter into the pancreatic duct, a pancreatic juice draining stimulant (secretin) is administered to remove the pure fluid from the pancreas.
  • ERCP endoscopic pancreatography
  • secretin a pancreatic juice draining stimulant
  • the measured CEA concentration is 0.1 to 10 ng / mL for healthy subjects (control) in Non-Patent Document 3 and 1 to 500 ng / mL for patients with pancreatic cancer, and 56 ⁇ 5 for healthy subjects (Control) in Non-Patent Document 4.
  • pancreatic cancer has been reported to be as high as 71.4% sensitivity and 93.3% specificity. That is, it has been shown that by using pure pancreatic juice collected by directly inserting a catheter into the pancreatic duct as a measurement sample, the same CEA inspection performance can be obtained even in another facility. This is probably because the pancreatic juice is collected by inserting the catheter directly into the pancreatic duct compared to the secretin test described above, so that it is not affected by bile and the like, and there is less variation in the sampling technique. It was.
  • this method requires a method of inserting a catheter into the pancreatic duct endoscopically, and requires a high level of skill for a doctor. Moreover, since there is a risk of developing a serious symptom of acute pancreatitis as an accidental onset of examination, it could be performed only for patients who were strongly suspected of having pancreatic disease.
  • An aspect of the present invention is to provide a detection method for detecting a pancreatic disease marker, which can reduce the risk of accidents and obtain a highly reliable result.
  • a method for detecting a pancreatic disease marker which comprises detecting a pancreatic disease marker in duodenal juice collected from a subject and containing naturally drained pancreatic juice.
  • the method for detecting a pancreatic disease marker according to (1) wherein the detection of the pancreatic disease marker measures the marker concentration and determines whether or not the concentration is a predetermined threshold value or more.
  • the pancreatic disease marker is CEA, The pancreatic disease is pancreatic cancer; The method for detecting a pancreatic disease marker according to (2), wherein the threshold value is a concentration in the range of 50 to 200 ng / mL.
  • a measurement kit for a marker of pancreatic disease in duodenal juice containing naturally drained pancreatic juice A kit for measuring a pancreatic disease marker, comprising a membrane on which a first antibody against the pancreatic disease marker is solid-phased.
  • a pancreatic juice drainage stimulating agent is obtained with high accuracy as in the case of measuring the CEA concentration in pure pancreatic juice directly collected from the pancreatic duct after administration of the pancreatic juice excretion stimulating agent.
  • a pancreatic disease marker such as CEA can be detected without using it and without inserting a catheter into the pancreatic duct. That is, there is no risk of accidents associated with the catheter insertion process into the pancreatic duct, and since it is simpler and less expensive than the conventional method, there is no suspicion of pancreatic disease by the method for detecting a pancreatic disease marker of the present invention.
  • the pancreatic juice test can be performed more safely on the patient. Therefore, it can be expected that the pancreatic cancer test is widely and generally spread by the method for detecting a marker for pancreatic disease of the present invention.
  • Example 1 it is the figure which showed the measurement result of the p-amylase density
  • emitted naturally according to the disease In Example 1, it is the figure which showed the CEA density
  • Example 1 it is the figure which showed the result of ROC (Receiver Operating Characteristic) analysis at the time of using the CEA density
  • ROC Receiveiver Operating Characteristic
  • pancreatic disease markers are various biomolecules such as proteins, nucleic acids, lipids, cells and the like contained in pancreatic juice, and are more effective in pancreatic diseases than non-affected individuals of pancreatic diseases.
  • the non-affected person of a pancreatic disease includes not only a healthy person but a diseased person other than a pancreatic disease.
  • pancreatic diseases include pancreatic cancer, IPMN (intraductal papillary mucinous tumor), MCN (mucinous cystic tumor), SCN (serous cystic tumor), NET (pancreatic endocrine tumor), chronic pancreatitis (CP), Examples include acute pancreatitis.
  • Pancreatic juice is a bodily fluid discharged from the pancreatic duct into the intestine of the duodenum.
  • duodenal juice intestinal fluid present in the intestinal tract of the duodenum
  • the naturally excreted pancreatic juice means pancreatic juice excreted from the pancreatic duct into the duodenal intestine without administration of a pancreatic juice excretion stimulator such as secretin.
  • pancreatic juice Since pancreatic juice is a digestive juice, it contains various digestive enzymes. These digestive enzymes exist in an inactive state in the pancreas, but are known to be activated after excretion into the duodenum. By activation of these various digestive enzymes, various biomolecules such as proteins, nucleic acids, lipids and cells contained in pancreatic juice are degraded and denatured after excretion into the duodenum. Therefore, when examining the target biomolecule in the pancreatic juice, it was considered that accurate measurement would not be possible if the pancreatic juice excreted into the duodenum was used as a measurement sample.
  • pancreatic disease markers in duodenal fluid including naturally excreted pancreatic juice
  • concentration of pancreatic disease markers in pure pancreatic juice collected directly from the pancreatic duct after stimulation with a pancreatic drainage stimulant It has been clarified by the present inventors that the presence or absence of pancreatic disease and the magnitude of the onset risk are reflected as well as the concentration. That is, the concentration of the pancreatic disease marker in the duodenal juice containing the naturally drained pancreatic juice is higher in those suffering from pancreatic disease than in those not suffering from pancreatic disease.
  • pancreatic disease marker in the duodenal juice collected from the subject by detecting the pancreatic disease marker in the duodenal juice collected from the subject and measuring its concentration, whether or not this subject suffers from the pancreatic disease and the risk of developing the pancreatic disease are determined by the conventional method.
  • the most accurate and reliable method can be examined with as high accuracy.
  • the method for detecting a marker for pancreatic disease according to an embodiment of the present invention is performed in a duodenal juice collected from a subject, It is characterized by measuring the concentration of a marker for pancreatic disease.
  • the method for detecting a marker for pancreatic disease of the present invention does not require stimulation with a pancreatic juice discharge stimulator, and thus can be carried out at a lower cost.
  • pancreatic juice after stimulation with a pancreatic juice discharge stimulant generally, pancreatic juice is collected 30 to 45 minutes after stimulation, but in the present invention, duodenal fluid collected in the intestinal tract of the duodenum is collected.
  • the catheter is not inserted into the pancreatic duct of the nipple, a body fluid as a measurement sample for detecting a pancreatic disease marker can be collected more non-invasively and easily. That is, the method for detecting a marker for pancreatic disease according to the present invention has no risk of accidental onset of tests such as acute pancreatitis, and therefore the pancreatic disease marker test that has so far only been performed only for patients with pancreatic disease from the risk Can be carried out more safely even for a subject whose presence or absence of onset of pancreatic disease is unknown.
  • the duodenal fluid used in the method for detecting a marker for pancreatic disease of the present invention is a fluid collected from the intestinal tract of the duodenum of a subject who has not been administered a pancreatic juice discharge stimulant.
  • the duodenal juice collected from anywhere in the intestinal tract of the duodenum may be used, the duodenal juice present in the second or third portion of the duodenum is preferable.
  • the first portion of the duodenum is directly connected from the pyloric part of the stomach, and there is a possibility of gastric juice contamination, and it is relatively difficult to fix the endoscope for collection and it may be difficult to collect Is for etc.
  • the method for collecting the duodenal juice is not particularly limited as long as it is a method capable of collecting the stored liquid in the intestinal tract of the duodenum.
  • duodenal fluid can be collected by suction means such as a syringe or vacuum pump connected to an endoscopic catheter.
  • suction means such as a syringe or vacuum pump connected to an endoscopic catheter.
  • the endoscope is inserted from the oral cavity to the duodenum, and the duodenal fluid present in the second and third portions of the duodenum is aspirated and collected using a catheter inserted through the canal channel.
  • the duodenal juice collected in the intestinal tract of the duodenum is collected and the pancreatic disease marker in the obtained duodenal juice May be inspected.
  • the collected duodenal juice is preferably subjected to a pancreatic disease marker measurement test immediately after collection or within a few hours.
  • the duodenal fluid that has been stored for a predetermined period after the collection is treated with the concentration of the disease marker. You may use for a measurement test.
  • the collected duodenal juice may be stored refrigerated or frozen, may be stored at room temperature, may be lyophilized, and stored as a frozen powder.
  • disassembly of the digestive enzyme in duodenal juice can also be preserve
  • a proteolytic enzyme inhibitor for a proteolytic enzyme that degrades the pancreatic disease marker protein it is preferable to mix abundant serine protease inhibitors in pancreatic juice.
  • a proteolytic enzyme inhibitor or the like may be mixed after collecting duodenal juice from a living body, and the duodenal juice can also be collected in a container in which a proteolytic enzyme inhibitor or the like is previously placed.
  • the collected duodenal juice may be used as it is in a measurement test for a pancreatic disease marker, or may be used after separating and removing solids such as cells by centrifugation or the like.
  • a diluted solution obtained by diluting the collected duodenal juice with an appropriate buffer or the like, or a solution obtained by adding various additives to the duodenal fluid or a diluted solution thereof may be used for a measurement test of a pancreatic disease marker.
  • the additive include a surfactant, a proteolytic enzyme inhibitor, a nucleolytic enzyme inhibitor, a pH adjuster, and a pH indicator.
  • the pancreatic disease marker detected in the method for detecting a marker for pancreatic disease of the present invention is a biomolecule whose concentration in the pancreatic juice is significantly higher in patients suffering from pancreatic disease than in non-affected individuals of pancreatic disease. There is no particular limitation as long as it is sufficient.
  • the pancreatic disease marker is preferably a biomolecule that is not easily affected by digestive enzymes contained in duodenal juice, such as glycoproteins and enzymes.
  • pancreatic disease markers to be detected in the method for detecting a pancreatic disease marker of the present invention examples include glycoproteins CEA, CA19-9 (for example, see Non-Patent Document 3 etc.), MUC-1 (KL-6) (for example, JP, 2006-308576, etc.), enzyme MMP2 (Matrix Metalloproteinase-2) (see, for example, Pancreas, 2002, vol.24, No.54, p344-347), MMP7 (Matrix Metalloproteinase-7) Etc.
  • substances that become significantly higher in pancreatic juice in patients suffering from pancreatic diseases such as S100P are raised.
  • the pancreatic disease marker detected in the method for detecting a pancreatic disease marker of the present invention is particularly preferably CEA.
  • CEA concentration in duodenal juice containing spontaneously drained pancreatic juice as an index, it is possible to examine the presence or risk of developing pancreatic cancer, IPMN, MCN, chronic pancreatitis, acute pancreatitis, and the like.
  • a marker for pancreatic disease in duodenal juice is detected using an antigen-antibody reaction.
  • an antigen antibody formed by contacting an antibody against a pancreatic disease marker (an antigen when the pancreatic disease marker is an antibody) with duodenal juice, which is immobilized on a solid phase The complex is detected on the solid phase.
  • an antibody against a pancreatic disease marker an antigen when the pancreatic disease marker is an antibody
  • the immobilized antibody (or antigen) A pancreatic disease marker is bound and the formed complex is detected.
  • pancreatic disease in which biomolecules in duodenal juice are immobilized in advance on a solid phase, and an antibody against a pancreatic disease marker (an antigen when the pancreatic disease marker is an antibody) is contacted with the solid phase.
  • the complex formed is detected by binding to the marker.
  • Examples of the solid phase for immobilizing an antigen or antibody include, for example, polymer membranes such as nitrocellulose membranes, gels such as agarose gels and SDS-PAGE gels, inner surfaces of containers such as plastic tubes and microplates, latex beads, magnetic beads Etc.
  • Examples of a method for detecting an antigen-antibody complex formed on an antigen or antibody immobilized on a solid phase include, for example, immunochromatography, Western blotting, dot plotting, slot blotting, immunoelectrophoresis, immunization Examples include diffusion methods, ELISA methods, immunoaggregation methods using latex beads, immunoassay methods using magnetic beads, SPR, and the like.
  • Antigen or antibody immobilization methods and these methods can be performed by conventional methods except that duodenal fluid is used as a measurement target and an antibody against a pancreatic disease marker (an antigen when the pancreatic disease marker is an antibody) is used. it can. It can also be detected in the liquid phase using an antigen-antibody reaction. In the case of detecting in the liquid phase, the binding between the labeled antibody and the antigen can be measured by FCS, FRET, or the like. The presence of the antigen can also be measured by molecular weight measurement such as TOF-MS.
  • pancreatic disease markers are preferably detected by an immunochromatography method or an ELISA method because they are rapid and simple and easy to quantitatively detect, and are detected by an immunochromatography method. It is more preferable.
  • a composite formed by dropping duodenal juice onto a nitrocellulose membrane in which an antibody against a pancreatic disease marker is immobilized on the membrane surface in advance and binding the pancreatic disease marker in the duodenal fluid to the immobilized antibody. Detect the body.
  • a labeled antibody pre-labeled with a fluorescent substance, gold colloid, enzyme or the like as an antibody that binds to this complex, this complex can be detected as a band.
  • the concentration of the pancreatic disease marker in the duodenal juice is determined qualitatively by visually comparing the density of the band detected using the duodenal juice with a calibration color sample prepared using a known concentration of the pancreatic disease marker. Can be measured automatically. It can also be easily determined by optically measuring the density of the band and comparing it with the density of the band similarly detected using a known concentration of pancreatic disease marker. In addition, a calibration curve representing the relationship between band density and pancreatic disease marker concentration should be prepared in advance, and the band density detected using duodenal juice can be measured optically and converted from the calibration curve. Thus, the concentration of the pancreatic disease marker in the duodenal juice can also be determined.
  • the concentration of the pancreatic disease marker in the duodenal juice containing the naturally drained pancreatic juice tends to be higher in affected individuals who develop pancreatic disease than in non-affected individuals with pancreatic disease. For this reason, the possibility of suffering from pancreatic disease in the subject can be determined using the concentration of the pancreatic disease marker in the duodenal juice of the subject.
  • Establish a threshold value that separates affected and non-affected individuals in advance measures the concentration of the pancreatic disease marker in the duodenal juice of the subject, and determines whether this concentration is greater than or equal to the predetermined threshold . When this concentration is equal to or higher than a predetermined threshold, it can be determined that the subject is likely to have pancreatic disease.
  • the pancreatic disease can be detected by measuring the concentration of the pancreatic disease marker in the duodenal fluid containing the naturally drained pancreatic juice and comparing it with a predetermined threshold value.
  • the threshold value for separating the affected and unaffected individuals of pancreatic disease can be set experimentally in consideration of the type of pancreatic disease marker, the detection method of the pancreatic disease marker, and the like. For example, for duodenal juice collected from a population known not to suffer from pancreatic disease and duodenal fluid collected from a population known to suffer from this disease, It can be set as appropriate by measuring the concentration of the pancreatic disease marker in the duodenal juice naturally discharged by the detection method and comparing the measured values of both populations.
  • the threshold value for separating an affected person of pancreatic cancer from an unaffected person is preferably a concentration in the range of 50 to 200 ng / mL. More preferably, the concentration is in the range of 100 to 150 ng / mL.
  • pancreatic diseases without subjective symptoms can be picked up widely. Further, if the CEA concentration is high, there is a high possibility that the pancreatic cancer has progressed, and therefore it can be determined that a rapid close examination and the start of treatment are necessary.
  • pancreatic disease marker is CEA
  • an antibody in which duodenal juice is immobilized on a membrane on an nitrocellulose membrane in which an anti-CEA antibody is immobilized on the membrane surface in advance is an epitope site.
  • immunochromatography in which an anti-CEA antibody is immobilized on the membrane surface in advance is an epitope site.
  • a complex composed of the immobilized anti-CEA antibody, CEA and labeled anti-CEA antibody is formed on the surface of the nitrocellulose membrane.
  • the formed band is detected as a band by the label in the labeled anti-CEA antibody.
  • the CEA concentration on the immunochromatography can be quantified from the density of the band by visual comparison with the band concentration of a color sample in which a band obtained when a predetermined concentration of CEA is added. Further, the CEA concentration can be converted by optically measuring the density of the band and converting it from a predetermined calibration curve or the like.
  • the intensity of the band on the immunochromatography is compared to the color swatch described for the 50 ng / mL and 200 ng / mL CEA concentration bands, or the intensity between these two bands, or When it is higher than the band of 200 ng / mL, it is positive (the subject from whom the duodenal fluid used for the measurement was collected suffers from pancreatic diseases such as pancreatic cancer, IPMN, MCN, chronic pancreatitis, and acute pancreatitis, particularly pancreatic cancer. It is highly possible that
  • CEA concentration is relatively low in diseases where there are many benign such as IPMN and MCN, and it is assumed that CEA concentration is high in advanced pancreatic cancer and advanced chronic pancreatitis. For this reason, it can be expected to determine the degree of morbidity of a specific pancreatic disease other than pancreatic cancer by setting an appropriate threshold.
  • the CEA concentration in naturally discharged duodenal juice is measured by a rapid kit such as an immunochromatography method, so that a positive / negative judgment can be made quickly and easily in an endoscope room where duodenal juice is collected. (Determining whether the subject has a pancreatic disease) can be performed. Therefore, by using the pancreatic disease marker detection method of the present invention, a screening test for pancreatic cancer that is safe, high-performance, and rapid can be performed. It can be judged immediately after collecting the liquid, and by promptly motivating and making a reservation for the detailed examination, it is possible to start treatment of pancreatic cancer quickly.
  • pancreatic disease marker measuring kit of the present invention is a kit for measuring a pancreatic disease marker in duodenal juice containing naturally drained pancreatic juice.
  • the disease marker is an antibody
  • it preferably includes a solid phase on which an antigen) is immobilized in advance, for example, a membrane on which the first antibody against a pancreatic disease marker is immobilized.
  • An example of this membrane is an immunochromatographic test strip.
  • This measurement kit also preferably has a second antibody that labels a marker for pancreatic disease.
  • the measurement kit may further include a duodenal fluid storage container in which a proteolytic enzyme inhibitor is previously stored.
  • Example 1 Duodenal juice was collected from 73 patients suspected of having pancreatic disease and the CEA concentration was measured. Insert the endoscope into the second portion of the duodenum in a patient who fasted overnight, and use the catheter for pancreatography (Olympus, product name: PR-130Q) to complete the second and third portions of the duodenum. The duodenal juice collected in the wall was collected. Collection was performed by aspirating a syringe connected to the proximal side of the catheter outside the endoscope. An average of about 1 mL of duodenal juice could be collected in about 2 to 3 minutes. In the first portion of the duodenum, the endoscope fell out to the stomach side, and stable collection was not possible.
  • duodenal juice discharged naturally 47 out of 73 cases were further intravenously injected with secretin (manufactured by Cairocrine), and after 2 to 3 minutes, the second and third portion of the duodenal wall
  • secretin manufactured by Cairocrine
  • the duodenal juice accumulated shallowly was collected in the same manner.
  • secretin stimulation about 1.5 mL to about 2 mL of duodenal juice could be collected in about 2 to 3 minutes.
  • image diagnosis or pathological examination was further performed on each patient, and a final diagnosis was performed.
  • pancreatic cancer As a result of the final diagnosis, among 73 cases, there were 41 cases of pancreatic cancer, 17 cases of IPMN, 2 cases of MCN, 6 cases of SCN, 3 cases of NET, and 4 cases of chronic pancreatitis (CP).
  • CP chronic pancreatitis
  • duodenal juice collected from 47 patients who were able to collect both naturally-extracted duodenal fluid and secreted duodenal fluid (naturally-exposed duodenal fluid and secreted after secretin stimulation)
  • P-amylase concentration and CEA concentration in the duodenal juice were measured.
  • the p-amylase concentration was measured by an enzyme method (Gal-G2-CNP substrate method).
  • the CEA concentration was measured by ELISA using a commercially available kit (manufactured by IBL).
  • FIG. 1 shows the p-type in each duodenal juice for 47 patients who were able to collect both the duodenal juice drained naturally (before secretin stimulation) and the duodenal fluid drained after secretin stimulation (after secretin). The measurement result of amylase concentration is shown. It was found that even the duodenal juice before administration of secretin contained approximately the same level of p-amylase as the duodenal fluid after administration of secretin.
  • p-Amylase is derived from pancreatic juice, and pancreatic juice derived from the pancreas is naturally excreted and contained in the duodenal juice, and components derived from pancreatic juice can be detected from the duodenal juice that has been excreted naturally. confirmed.
  • FIG. 2 shows the CEA concentration in the duodenal juice excreted spontaneously
  • FIG. 3 shows the CEA concentration in the duodenal juice excreted after secretin stimulation.
  • the CEA concentration in the duodenal juice that was naturally excreted (no secretin administration) in this example was the same as that of pure pancreatic juice collected by cannulation in the nipple.
  • the CEA concentration was in the same concentration range. From these results, it was found that even when the CEA concentration in the duodenal juice discharged naturally was measured, the same pancreatic disease discrimination effect as that obtained when the CEA concentration of pure pancreatic juice was measured was obtained.
  • the CEA concentration in the duodenal juice of 73 cases spontaneously excreted (without administration of secretin) and the CEA concentration in the duodenal juice are shown in FIG.
  • the CEA concentration in duodenal juice was high in pancreatic cancer, and IPMN and chronic pancreatitis (CP) as treatment targets for pancreatic disease also showed high values.
  • CP chronic pancreatitis
  • NET malignant NET resulted in higher CEA concentration than benign NET data.
  • the SCN of the benign tumor that was the subject of follow-up was low, and the result was consistent with FIG.
  • ROC Receiveiver Operating Characteristic analysis was performed to examine whether the CEA concentration in the duodenal juice excreted spontaneously can be used as a marker for distinguishing pancreatic cancer from benign tumors (SCN in the present invention).
  • ROC analysis was performed using PASW statistics ver. 18 (manufactured by IBM). The analysis results are shown in FIG. As a result, the cut-off value (threshold value) for distinguishing pancreatic cancer from benign tumors was almost equivalent to the CEA concentration in pure pancreatic juice and the CEA concentration in duodenal juice collected after administration of secretin.
  • the sensitivity of detection of pancreatic cancer in this example was 71% sensitivity and 100% specificity, which was superior to the case where CEA concentration in pure pancreatic juice in the previous report was used as an index.
  • a cut-off value for distinguishing between pancreatic cancer and benign tumor was set within a range of 30 to 250 ng / mL, and sensitivity and specificity for each cut-off value were calculated. Table 3 shows the calculation results. As a result, when the cut-off value was set from 100 to 150 ng / mL, even when the specificity was 80% or more, the sensitivity was 70% or more, and a sensitivity having utility as a test was obtained. In addition, when the cut-off value is set, it becomes possible to detect pancreatic cancer from diseases such as MCN, and a test with higher specificity of pancreatic cancer can be expected. In addition to pancreatic cancer, NET can be expected to be benign or malignant.
  • the specificity is 50%, which is halved compared with the case where the cut-off value is set from 100 to 150 ng / mL, but the sensitivity is 93%, which is very sensitive to pancreatic cancer. Inspection can be performed.
  • Example 2 Using a commercially available CEA immunochromatography kit (product name: Lana Mammo Card CEA, manufactured by Nippon Kayaku Co., Ltd.), CEA in the naturally excreted duodenal fluid sample used in Example 1 was detected. The CEA concentration was visually determined by comparing the color sample of the band attached to the kit with the intensity of the immunochromatographic band detected from each duodenal fluid specimen. As a result, there was a correlation between the band density of the duodenal fluid specimen when compared with 100 ng / mL and 400 ng / mL of the color sample and the measured value of CEA concentration by ELISA, and the CEA concentration in the duodenal juice was determined by immunochromatography. It was confirmed that it could be measured by the method.
  • a commercially available CEA immunochromatography kit product name: Lana Mammo Card CEA, manufactured by Nippon Kayaku Co., Ltd.
  • Example 3 A protease inhibitor (product name: Complete, manufactured by Roche) is placed in advance in a syringe connected to the proximal side of the catheter outside the endoscope, and 47 patients out of Example 1 from Duodenal juice was aspirated.
  • the aspirated duodenal fluid was mixed with a protease inhibitor in a syringe, then transferred to a tube and stored frozen.
  • duodenal fluid collected via a catheter that did not previously contain a protease inhibitor in the syringe was similarly transferred to a tube and stored frozen.
  • the CEA concentration and S100P concentration of each duodenal juice after storage were measured.
  • the CEA concentration was measured in the same manner as in Example 1.
  • concentration was measured by ELISA method using the commercially available kit (made by Cyclex).
  • Tables 4 and 5 show the measurement results of CEA concentration and S100P concentration in duodenal juice by disease.
  • the CEA concentration the duodenal juice preserved with the addition of the protease inhibitor (in Table 4, “with inhibitor”) and the duodenal juice preserved without the addition of the protease inhibitor (inhibited in Table 4, “inhibition”). It was found that there was not much difference in concentration with no agent.
  • the S100P concentration is higher in the duodenal juice preserved with the addition of the protease inhibitor (in Table 5, “with inhibitor”) and in the duodenal juice preserved without the addition of the protease inhibitor (inhibited in Table 5, “inhibition”). Concentration was significantly higher than "no agent”).
  • the pancreatic disease marker detection method of the present invention is safe without risk of developing acute pancreatitis and measures CEA concentration in pure pancreatic juice directly collected from a catheter inserted into the pancreatic duct after stimulation of pancreatic juice drainage Since the pancreatic disease marker can be detected with the same accuracy as the case, it can be used in the field of analyzing pancreatic juice, particularly in the field of clinical examination and the like.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PCT/JP2012/072712 2011-09-13 2012-09-06 膵疾患マーカーの検出方法 WO2013038981A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201280043445.7A CN103782175A (zh) 2011-09-13 2012-09-06 胰腺病标记物的检出方法
EP12832566.9A EP2757377A4 (en) 2011-09-13 2012-09-06 METHOD FOR DETECTION OF PANCREATIC DISEASE MARKER
US14/199,136 US20140186863A1 (en) 2011-09-13 2014-03-06 Method for detecting pancreatic disease marker

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011-199684 2011-09-13
JP2011199684 2011-09-13

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/199,136 Continuation US20140186863A1 (en) 2011-09-13 2014-03-06 Method for detecting pancreatic disease marker

Publications (1)

Publication Number Publication Date
WO2013038981A1 true WO2013038981A1 (ja) 2013-03-21

Family

ID=47883212

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2012/072712 WO2013038981A1 (ja) 2011-09-13 2012-09-06 膵疾患マーカーの検出方法

Country Status (5)

Country Link
US (1) US20140186863A1 (zh-TW)
EP (1) EP2757377A4 (zh-TW)
JP (1) JPWO2013038981A1 (zh-TW)
CN (1) CN103782175A (zh-TW)
WO (1) WO2013038981A1 (zh-TW)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013190867A1 (ja) * 2012-06-22 2013-12-27 オリンパス株式会社 膵液成分含有試料の調製方法、及び膵液成分を含有する生体試料の室温保存用キット
WO2015001831A1 (ja) 2013-07-02 2015-01-08 オリンパス株式会社 膵疾患マーカー検出用十二指腸液試料の決定方法、及び膵疾患マーカーの検出方法
JP2015011011A (ja) * 2013-07-02 2015-01-19 オリンパス株式会社 膵疾患マーカー検出用十二指腸液試料の選定方法、及び膵疾患マーカーの検出方法
JP5735670B1 (ja) * 2014-01-14 2015-06-17 田中貴金属工業株式会社 免疫クロマト分析方法、免疫クロマト分析装置および免疫クロマト分析キット
JP5974190B2 (ja) * 2014-05-26 2016-08-23 オリンパス株式会社 膵癌進行度を示すための方法
JP6017724B1 (ja) * 2015-02-25 2016-11-02 オリンパス株式会社 十二指腸液試料の膵液由来成分検出用試料としての適性評価方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106537150B (zh) * 2014-07-23 2019-03-26 奥林巴斯株式会社 胰脏疾病判定方法
CN105021825B (zh) * 2015-07-09 2016-08-17 陈勇 一种检测胰腺癌相关多肽dap44的elisa试剂盒

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08160047A (ja) * 1994-11-30 1996-06-21 Meiji Seika Kaisha Ltd 免疫学的測定方法
WO2005015217A1 (ja) * 2003-08-11 2005-02-17 Kyowa Medex Co., Ltd. 測定対象物測定器具、測定装置および測定方法
JP2006308576A (ja) * 2005-03-31 2006-11-09 Eisai Co Ltd 膵液による膵管内乳頭粘液性腺癌および膵臓癌の検出法及び検出キット
JP2010025770A (ja) * 2008-07-18 2010-02-04 Noguchi Inst α−アミラーゼアイソザイムの識別法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444879A (en) * 1981-01-29 1984-04-24 Science Research Center, Inc. Immunoassay with article having support film and immunological counterpart of analyte
US20020041872A1 (en) * 1996-04-12 2002-04-11 Malaya Chatterjee Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
CN1147729C (zh) * 1998-12-30 2004-04-28 卢氏实验公司 半定量金标免疫层析测试条及诊断盒
CN2672656Y (zh) * 2003-12-29 2005-01-19 牛旗 诊断试剂条
CA2712505C (en) * 2008-01-17 2018-10-23 Fox Chase Cancer Center Biomarkers for the diagnosis and treatment of pancreatic cancer
CN101750491A (zh) * 2008-12-16 2010-06-23 陈洁 癌症唾液快速检测试剂
CN101762700A (zh) * 2009-06-24 2010-06-30 北京科美东雅生物技术有限公司 一种定量检测血液中癌胚抗原的磁性免疫层析试纸条及制备方法
US8586384B2 (en) * 2011-04-05 2013-11-19 Olympus Corporation Method of collecting duodenal specimen to detect upper digestive system disease without using pancreatic or bile stimulant
US8529547B2 (en) * 2011-04-05 2013-09-10 Olympus Corporation Method of collecting specimen and method of diagnosing subject to detect upper digestive system disease

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08160047A (ja) * 1994-11-30 1996-06-21 Meiji Seika Kaisha Ltd 免疫学的測定方法
WO2005015217A1 (ja) * 2003-08-11 2005-02-17 Kyowa Medex Co., Ltd. 測定対象物測定器具、測定装置および測定方法
JP2006308576A (ja) * 2005-03-31 2006-11-09 Eisai Co Ltd 膵液による膵管内乳頭粘液性腺癌および膵臓癌の検出法及び検出キット
JP2010025770A (ja) * 2008-07-18 2010-02-04 Noguchi Inst α−アミラーゼアイソザイムの識別法

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
FARINI ET AL., HEPATO-GASTROENTEROLOGY, vol. 27, 1980, pages 213 - 216
HEPATO-GASTROENTEROLOGY, vol. 46, no. 46, 1999, pages 31 - 37
JOAO A. PAULO: "Optimized sample preparation of endoscopic collected pancreatic fluid for SDS-PAGE analysis", ELECTROPHORESIS, vol. 31, no. 14, July 2010 (2010-07-01), pages 2377 - 2387, XP055092467 *
PANCREAS, vol. 24, no. 54, 2002, pages 344 - 347
PANCREAS, vol. 9, no. 6, 1994, pages 741 - 747
ROLNY ET AL., SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, vol. 12, 1977, pages 759 - 763
See also references of EP2757377A4 *
YOSHIHARU MOTOO ET AL.: "Sensitivity and specificity of tumor markers in cancer diagnosis", THE JAPANESE JOURNAL OF CLINICAL MEDICINE, vol. 54, no. 6, 1996, XP008171244 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013190867A1 (ja) * 2012-06-22 2013-12-27 オリンパス株式会社 膵液成分含有試料の調製方法、及び膵液成分を含有する生体試料の室温保存用キット
US9376675B2 (en) 2012-06-22 2016-06-28 Olympus Corporation Method for preserving components of pancreatic juice in a sample, and kit for preserving components of pancreatic juice in a sample
JPWO2013190867A1 (ja) * 2012-06-22 2016-02-08 オリンパス株式会社 膵液成分含有試料の調製方法、及び膵液成分を含有する生体試料の室温保存用キット
CN105358987A (zh) * 2013-07-02 2016-02-24 奥林巴斯株式会社 胰腺病标记物检测用十二指肠液试样的确定方法、以及胰腺病标记物的检测方法
WO2015001831A1 (ja) 2013-07-02 2015-01-08 オリンパス株式会社 膵疾患マーカー検出用十二指腸液試料の決定方法、及び膵疾患マーカーの検出方法
JP2015011011A (ja) * 2013-07-02 2015-01-19 オリンパス株式会社 膵疾患マーカー検出用十二指腸液試料の選定方法、及び膵疾患マーカーの検出方法
JP6042985B2 (ja) * 2013-07-02 2016-12-14 オリンパス株式会社 膵疾患マーカー検出用十二指腸液試料の決定方法、及び膵疾患マーカーの検出方法
JP5735670B1 (ja) * 2014-01-14 2015-06-17 田中貴金属工業株式会社 免疫クロマト分析方法、免疫クロマト分析装置および免疫クロマト分析キット
JP2015132548A (ja) * 2014-01-14 2015-07-23 田中貴金属工業株式会社 免疫クロマト分析方法、免疫クロマト分析装置および免疫クロマト分析キット
WO2015108082A1 (ja) * 2014-01-14 2015-07-23 田中貴金属工業株式会社 免疫クロマト分析方法、免疫クロマト分析装置および免疫クロマト分析キット
JP5974190B2 (ja) * 2014-05-26 2016-08-23 オリンパス株式会社 膵癌進行度を示すための方法
EP3151008A4 (en) * 2014-05-26 2017-11-22 Olympus Corporation Pancreatic cancer determination method
JP6017724B1 (ja) * 2015-02-25 2016-11-02 オリンパス株式会社 十二指腸液試料の膵液由来成分検出用試料としての適性評価方法
US9809837B2 (en) 2015-02-25 2017-11-07 Olympus Corporation Method for evaluating suitability of duodenal fluid sample as sample for detecting pancreatic fluid-derived components

Also Published As

Publication number Publication date
JPWO2013038981A1 (ja) 2015-03-26
US20140186863A1 (en) 2014-07-03
EP2757377A1 (en) 2014-07-23
CN103782175A (zh) 2014-05-07
EP2757377A4 (en) 2015-04-22

Similar Documents

Publication Publication Date Title
WO2013038981A1 (ja) 膵疾患マーカーの検出方法
US8586384B2 (en) Method of collecting duodenal specimen to detect upper digestive system disease without using pancreatic or bile stimulant
US8529547B2 (en) Method of collecting specimen and method of diagnosing subject to detect upper digestive system disease
Abdel-Razik et al. Insulin-like growth factor-1 and vascular endothelial growth factor in malignant and benign biliary obstructions
Cotten Evaluation of exocrine pancreatic function
US6905833B2 (en) Method of diagnosing breast cancer using nipple fluid
US20230055395A1 (en) Marker for pancreatic cancer and intraductal papillary mucinous neoplasms
KR20200049647A (ko) 반려동물에서 종양질병의 보조적 진단을 위한 바이오마커 검사방법
JP6141123B2 (ja) 膵疾患マーカー検出用十二指腸液試料の選定方法、及び膵疾患マーカーの検出方法
CN107271672B (zh) 外泌体p-ERK在制备结直肠癌诊断产品中的应用
US20220137041A1 (en) Device for methods of detecting cancer
US20100323374A1 (en) Serum Biomarkers for Diagnosing Liver Fibrosis and Method for Measuring the Same
CN114814224A (zh) 乳头溢液中的Hsp90α在乳腺癌中的应用
JP6042985B2 (ja) 膵疾患マーカー検出用十二指腸液試料の決定方法、及び膵疾患マーカーの検出方法
US10302659B2 (en) Method for evaluating the possibility of suffering from pancreatic disease
JP2021038990A (ja) 大腸がん罹患のリスクを評価するための方法
WO2014054729A1 (ja) 肝臓・胆道疾患マーカーの検出方法
EP4249601A1 (en) Method for assisting determination on adaptability of esophageal cancer to endoscopic therapy, method for determining adaptability of esophageal cancer to endoscopic therapy, method for collecting data for use in determination on adaptability of esophageal cancer to endoscopic therapy, method for diagnosing adaptability of esophageal cancer to endoscopic therapy, in vitro method for assisting determination on adaptability of esophageal cancer to endoscopic therapy, method for testing on adaptability of esophageal cancer to endoscopic therapy, method for diagnosing adaptability of esophageal cancer to endoscopic therapy, diagnosis kit, and method for treating esophageal cancer
US20230228757A1 (en) Method for judging risk of suffering kidney cancer
RU2580309C1 (ru) Способ иммунодиагностики рака желудка
EA043731B1 (ru) Способ комплексной диагностики заболеваний органов жкт (желудка, кишечника)
JP2003527583A (ja) 胆管−膵臓系疾患を診断する方法
WO2016060382A1 (ko) 췌장암 진단용 조성물 및 이를 이용한 췌장암 진단방법

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12832566

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2013533636

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2012832566

Country of ref document: EP